ACHE and memory impairment: For instance, in mouse models of scopolamine-induced memory impairment, the administration of SFN (10 or 50 mg/kg) to C57BL/6 mice via oral gavage for 2 weeks significantly reduced AChE activity in the frontal cortex [24].